Next-Generation Sequencing-Based Panel Testing for Myeloid Neoplasms
Our ability to interrogate a broad array of genetic alterations in myeloid neoplasm has increased significantly with the advance in next-generation sequencing (NGS). In addition to morphologic examination, flow cytometry, and cytogenetics, NGS-based testing can add additional information to the diagnostic workup. More than a dozen myeloid-focused NGS-based panels are now available from commercial and academic laboratories. In this review, we examine the content of these panels in the context of our current understanding of driver alterations in myeloid neoplasms. With improved turnaround time, decreasing costs, and an expanding knowledge of the therapeutic and prognostic significance of the detected variants, NGS-based panel testing is likely to play a major role in the management of patients with myeloid neoplasm in the coming decade.
KeywordsNext-generation sequencing Myeloid neoplasm Acute myeloid leukemia Myelodysplastic syndromes
Compliance with Ethics Guidelines
Conflict of Interest
Dr. Frank C. Kuo and Dr. Fei Dong each declare no potential conflicts of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance
- 7.OncoPlex [Internet]. Available from: http://tests.labmed.washington.edu/UW-OncoPlex.
- 8.FoundationOne [Internet]. Available from: http://foundationone.com/docs/FM_TechnicalOverview_HEM-I-001-20150105.pdf.
- 9.RHP URL [Internet]. Available from: http://bwhpathology.partners.org/rhp - camd.aspx.
- 10.Neogenomics [Internet]. Available from: http://www.neogenomics.com/neotype-Myeloid-Disorders-profile.htm.
- 11.Quest myeloid panel [Internet]. Available from: http://education.questdiagnostics.com/faq/FAQ160.
- 12.ARUP myeloid [Internet]. Available from: http://ltd.aruplab.com/Tests/Pub/2011117.
- 13.Knight myeloid [Internet]. Available from: http://www.knightdxlabs.com/home/test-details?id=GeneTrails+AML+MDS+Genotyping+Panel.
- 14.U penn CPD. Available from: http://www.pennmedicine.org/personalized-diagnostics/services.html.
- 15.BCW [Internet]. Available from: https://www.bcw.edu/cs/groups/public/documents/document/dgvz/df9k/∼edisp/ngs_hemeonc_test_desc.pdf.
- 16.Agilent [Internet]. Available from: http://www.chem.agilent.com/Library/datasheets/Public/AML DataSheet 5991-5058EN.pdf?cid=g011488.
- 17.Fulgent [Internet]. Available from: http://fulgentdiagnostics.com/test/cancer-2800/.
- 18.ResponseGenetics [Internet]. Available from: http://www.responsegenetics.com/wp-content/uploads/2014/04/NGS-Panels-Sheet-V3_JM-Rev.-5.23.14.pdf.
- 19.Genoptix [Internet]. Available from: http://www.genoptix.com/uploads/files/genoptix-biopharma-dos.pdf.
- 20.Rainedance [Internet]. Available from: http://raindancetech.com/thunderbolts-myeloid-panel/.
- 21.Trusight Myeloid [Internet]. Available from: http://www.illumina.com/products/trusight-myeloid.html.
- 26.Kottaridis PD, Gale RE, Frew ME, Harrison G, Langabeer SE, Belton AA, et al. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood. 2001;98:1752–9.CrossRefPubMedGoogle Scholar
- 34.Maxson JE, Luty SB, MacManiman JD, Abel ML, Druker BJ, Tyner JW. Ligand independence of the T618I mutation in the colony-stimulating factor 3 receptor (CSF3R) protein results from loss of O-linked glycosylation and increased receptor dimerization. J Biol Chem. 2014;289:5820–7.CrossRefPubMedCentralPubMedGoogle Scholar
- 37.•Tefferi A, Guglielmelli P, Lasho TL, Rotunno G, Finke C, Mannarelli C, et al. CALR and ASXL1 mutations-based molecular prognostication in primary myelofibrosis: an international study of 570 patients. Leukemia. 2014;28:1494–500. This study looked at large numbers of patients with and without CALR mutations with very long follow-up and confirmed the clinical characteristics of the CALR-mutated group and showed the similar outcome between these groups.CrossRefPubMedGoogle Scholar
- 50.Piazza R, Valletta S, Winkelmann N, Redaelli S, Spinelli R, Pirola A, et al. Recurrent SETBP1 mutations in atypical chronic myeloid leukemia. 2013;45(1):18–24.Google Scholar
- 53.Meggendorfer M, Bacher U, Alpermann T, Haferlach C, Kern W, Gambacorti-Passerini C, et al. SETBP1 mutations occur in 9% of MDS/MPN and in 4% of MPN cases and are strongly associated with atypical CML, monosomy 7, isochromosome i(17)(q10), ASXL1 and CBL mutations. Leukemia. 2013;27:1852–60.CrossRefPubMedGoogle Scholar
- 62.•Krauth M, Alpermann T, Bacher U, Eder C, Dicker F, Ulke M, et al. WT1 mutations are secondary events in AML, show varying frequencies and impact on prognosis between genetic subgroups. Leukemia. 2014. doi: 10.1038/leu.2014.243. This large study examined more than 3000 cases of AML and found WT1 mutations in 5 % of patients with independent adverse effect of EFS besides age and FLT3-ITD status.
- 71.Brooks AN, Choi PS, De Waal L, Sharifnia T, Imielinski M, Saksena G, et al. A pan-cancer analysis of transcriptome changes associated with somatic mutations in U2AF1 reveals commonly altered splicing events. PLoS One. 2014;9(1)9-23.Google Scholar
- 76.•Lindsley RC, Mar BG, Mazzola E, Grauman PV, Shareef S, Allen SL, et al. Acute myeloid leukemia ontogeny is defined by distinct somatic mutations. Blood. 2014;2014-11-610543. The classification of AML into de novo, secondary and therapy-related depends on the availability of detailed clinical history and is sometimes subject. This study looks for genetic classifiers and identify SF3B1, U2AF1, ZRSR2, STAG2, ASXL1, EZH2, BCOR and SRSF2 as marker for secondary AML which included some AML previously thought to be de novo or therapy-related. Google Scholar
- 81.•Genovese G, Kähler AK, Handsaker RE, Lindberg J, Rose SA, Bakhoum SF, et al. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N Engl J Med. 2014;371:2477–87. This and the previous studies looked at large cohort of individuals with no known hematologic abnormalities and found variants in genes known to be associated with myeloid neoplasm. The frequency and allele fractions of these alterations increase with age. It remains to be seen whether these alterations are “pre-neoplastic” or not.Google Scholar
- 82.•Jaiswal S, Fontanillas P, Flannick J, Manning A, Grauman PV, Mar BG, et al. Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J Med. 2014;371:2488–98. This and the previous studies looked at large cohort of individuals with no known hematologic abnormalities and found variants in genes known to be associated with myeloid neoplasm. The frequency and allele fractions of these alterations increase with age. It remains to be seen whether these alterations are “pre-neoplastic” or not.CrossRefPubMedGoogle Scholar